Opinion

Video

Standard-of-Care Regimens for First-Line Treatment of HER2+ mBC

The panel provides comprehensive insights on approaching first-line treatment of patients with HER2+ metastatic breast cancer and the role of neratinib.

Related Videos
Andrew Davis, MD
Adrienne G. Waks, MD, Dana-Farber Cancer Institute
Video 8 - 2 KOLs are featured in, "Emerging Trials in the Management of HR+/HER2- mBC"
Video 7 - 2 KOLs are featured in, "Adverse Event Data and Management for Optimal Quality of Life in HR+/HER2- mBC"
4 KOLs are featured in this series
4 KOLs are featured in this series
4 KOLs are featured in this series
4 KOLs are featured in this series
5 KOLs are featured in this peer exchange